XRCC3 and central nervous system cancer: When stratified by the grade of glioma, patients with stage IV glioma had a significantly higher frequency of the XRCC3 241 MetMet genotype (OR=1.61; 95% CI: 1.06–2.44; P=0.03; Table III).